Inhibikase Therapeutics, Inc. (IKT) › Cash & EquivalentsInhibikase Therapeutics, Inc. (IKT) — Cash & EquivalentsAnnual figures by period end, from SEC filings.2021-12-31: $40.75M2022-12-31: $7.19M2023-12-31: $9.20M2024-12-31: $97.50M2025-12-31: $178.80M$178.80M2021-12-31Cash & Equivalents (USD)2025-12-31Period endedCash & EquivalentsChange YoYSource filing2025-12-31$178.80M+83.4%2026-03-26Balance as of period end2024-12-31$97.50M+959.8%2026-03-26Balance as of period end2023-12-31$9.20M+28.0%2025-03-27Balance as of period end2022-12-31$7.19M-82.4%2024-03-27Balance as of period end2021-12-31$40.75M—2023-03-31Balance as of period endOther metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)